BioSpace News Archive

UroGen Pharma Ltd. announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain investors in lieu of issuing ordinary shares, pre-funded warrants to purchase 1,142,857 ordinary shares at a purchase price of $17.499 per pre-funded warrant, which equals the public offering price per ordinary share less the $0.001 per share exercise price for each pre-funded warrant.

Gan & Lee Pharmaceuticals announced the presentation of three abstracts featuring their investigational products at the American Diabetes Association’s 84th Scientific Sessions.

CLINUVEL announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.